Scrip 100: R&D Paths Of Top 50 Pharma
Executive Summary
How has R&D spending in the pharmaceutical industry changed over the last decade? While the R&D collective picture for Big Pharma may not have changed much, individual company stories differ markedly.
You may also be interested in...
CSL Looks Beyond Organic Growth To External Innovation
CSL Ltd.'s sales grew 15% in its last fiscal year and are expected to grow about 8% in FY 2018, but the Australia-based company is looking beyond its plasma protein expertise to outside innovation to help boost future revenue.
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.